Member Info for Kaeren

Man in the moon is going to be CEO , he is the option, as he can work remotely.

Yes CS , new cases of Clade 1b announced.

https://x.com/KilkennyTed/status/1853542251017973998?t=-Kui6tMe2_nikiekCrMajA&s=19

https://x.com/KilkennyTed/status/1853446787001876814?t=SQeCze1xjh4WqU2BlOVxRw&s=19

No comment from me on either candidate, as not a political debating forum.

This caught my attention. Might need a lot more tests, for numerous ' stuff ' 🤔

https://x.com/Kit_Yates_Maths/status/1853547609501143286?t=de7q4eBV4tjKkMRB0lOvVw&s=19

I'm not sure if it has been discussed, but what is the ball park no for revenue generation from the Oct to April trial ? Is it adequate to extend cashflow runway or are we talking 100k ? Sorry if I've missed , been hell of a long work day.

Haven't read board today but did listen to the Dutch chap and it was fascinating.

My interpretation as non medical.

Big trials in Holland . He said in Europe they haven't used Clod as first line treatment for x years. They used two other drugs.

But realised increased bleeding. So extensive trial with Clod & asprin using a genetic test first to ensure clod correct pathway. Patient would be first given other drug then within x hours given genetic test or lab test. The latter was not as good as took days. Proven clod and asprin best choice as far cheaper and better results. The other drugs were substantially more expensive , but he mentioned patent or ip expiring so would become cheaper , but still more expensive then clod and because much stronger more bleeding and worse patient outcome.

Basically extolling the virtues of genetic test and clod. However, currently, not the recommended pathway in Europe. Sorry being lazy and not looking up names of the other drugs.

Reimbursement for drugs was also discussed.

Worth listening to. They used Spartanb& Cube.

Again, huge potential , but when ???

Put very simply , having read the drivel , it was the principal Geologist Lorna B ( now CEO ) who was 100 % responsible on site for selection of the dusters and not David M. That is no negative reflection on LB as she appears to have had a sterling career thus far. I shall make no further comments on HE1, as folks I've conversed with & respect are invested there. However to make such derogatory comments about someone who left the company in a strong position & was even asked to stay on to ensure a smooth transition , is as far from being sacked as one could imagine.

I mooted the idea of a Novacyt tie up on the NCYT board last week. The current MCAP of GDR would mean NCYTs CAB would be wiped by a takeover at double current GDR Share price.

Yeah could offer substantially less if GDR & shareholders were interested. Point is , why offer anything when there is no forward book of sales , buy potential ? Well that has existed for years , but as of today hasn't materialised.

Perhaps a % purchase / buy in , could alleviate GDRs cash flow issues, but that would cause dilution as would a placing. They can get a commercial loan as soon as they have contracts, chicken & egg , funds diminishing and no solid sizeable contracts on the horizon. We know this is a fact , because if there were any then we would be told ASAP as they'd have a material impact on the share price.

Very frustrating position for GDR , as on the cusp of market breakthrough imo.

Only rude girls shout 🤪

I've gone cross-eyed trying to read about mass spectrometer tools & neutron pulsers 🙄

Might as well not have bothered , didn't understand a bloody word. Think I'll just wait .. duh .

Thx Trojan , well that makes the timeline very clear.

Brent that is what I believe is happening & the same exercise will be performed for each depth tested. Dunno about which lab & where but think news could drop at any time & don't envisage an extended wait period.

RNS 21/10/2024

If multiple formations are deemed suitable for testing, each zone will be tested independently from the bottom-up to allow for isolated tests over each interval.

RNS 24/10/2024

Production casing has been run to 8,130ft and cemented. The Company will run cased-hole wireline prior to perforating target zones for testing, with samples of any gas recovered sent to an external laboratory for gas composition analysis.

The Company will test multiple formations from the bottom of the hole upwards.⭐️ If initial results of a perforation are positive the Company will report gas composition to the market ⭐️and perform an extended well test on the interval before moving on to the next horizon.

It isn't difficult to ignore, the future trajectory of this sp is entirely dependent on results from the two drills. Sp will be rangebound until then.

The only thing that is of any relevance now to holders is what Helix have to announce.

Good results and we head North and those not holding will be late to the party.

Going thru what ? The announcement was only released yesterday , no contract exists yet (hopefully one forthcoming)

Agree Stephen , just had time to read fully.

I would be extremely surprised if Scotland didn't roll out the test. It would be ludicrous to select an option that didn't compare favourably against Genedrive. A very positive report.

I've messaged GDR for all it's worth , asking why they haven't announced the SHTG findings.

Appreciate inf only released this morning but people read RNS's not chat boards and the market not aware , never mind potential increase in revenue.

Slacker , I reckon you should write a short instruction manual for dewampers.

One short chapter on multiple identities

Long chapter on how to say the same thing in a 1000 different ways.

Short chapter on caps locks and emoji use.

I hear you , as I said , a possible maybe as to reason for joining. No more, no less. Thx for responses. Hard to hear the adults with the rollox being posted on here.

Yes KT aware , but very short on funds. Wouldn't surprise me to see a stake taken .

Two great products.

One a test for babies to prevent hearing loss.

Caused by administration of a commonly used antibiotic , selected as antibiotic of choice for multiple reasons but can cause deafness. The test checks if an adverse reaction to the antibiotic could result in deafness, thus determining preferred antibiotic. NICE approved and rolled out in Manchester and Brighton currently. Looking for national rollout and increased global sales.

Stroke test.

Standard after stroke to administer clodriphil & asprin. Clod doesn't work in a high percentage of patients , after stroke fast treatment a necessity, lab tests take days , genedrive have Nice approved POCT test , again looking for national rollout. Pathway to take up slow , cash issue.

Just a brief v simple explanation and was just a possible maybe.